Cargando…

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

PURPOSE: In 2017, the Geneva Alzheimer’s disease (AD) strategic biomarker roadmap initiative proposed a framework of the systematic validation AD biomarkers to harmonize and accelerate their development and implementation in clinical practice. Here, we use this framework to examine the translatabili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bischof, Gérard N, Dodich, Alessandra, Boccardi, Marina, van Eimeren, Thilo, Festari, Cristina, Barthel, Henryk, Hansson, Oskar, Nordberg, Agneta, Ossenkoppele, Rik, Sabri, Osama, Giovanni, B Frisoni G, Garibotto, Valentina, Drzezga, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175320/ https://www.ncbi.nlm.nih.gov/pubmed/33590274 http://dx.doi.org/10.1007/s00259-020-05156-4

Ejemplares similares

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
por: Wolters, E. E., et al.
Publicado: (2021)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
por: Boccardi, Marina, et al.
Publicado: (2021)

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
por: Ashton, N. J., et al.
Publicado: (2021)

Assessment of Tau Tangles and Amyloid-β Plaques Among Super Agers Using PET Imaging
por: Hoenig, Merle C., et al.
Publicado: (2020)

Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils
por: Zhou, Yang, et al.
Publicado: (2021)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease
por: Bischof, Gérard N., et al.
Publicado: (2016)

Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases
por: Malarte, Mona-Lisa, et al.
Publicado: (2020)

Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer’s Tauopathy
por: Murugan, N. Arul, et al.
Publicado: (2021)

Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease
por: Pfeil, Julia, et al.
Publicado: (2021)

Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils
por: Li, Junhao, et al.
Publicado: (2023)

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
por: Walker, Zuzana, et al.
Publicado: (2018)

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
por: Murugan, N. Arul, et al.
Publicado: (2019)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

Feasibility of short imaging protocols for [(18)F]PI-2620 tau-PET in progressive supranuclear palsy
por: Song, Mengmeng, et al.
Publicado: (2021)

A multicenter comparison of [(18)F]flortaucipir, [(18)F]RO948, and [(18)F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2021)

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

Ethnic comparison of pharmacokinetics of (18)F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects
por: Senda, Michio, et al.
Publicado: (2014)

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease
por: Ossenkoppele, Rik, et al.
Publicado: (2019)

Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity
por: Pereira, Joana B, et al.
Publicado: (2019)

Binding characteristics of [(18)F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET
por: Song, Mengmeng, et al.
Publicado: (2021)

Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
por: Malarte, Mona-Lisa, et al.
Publicado: (2022)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Early-phase [(18)F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury
por: Beyer, Leonie, et al.
Publicado: (2020)

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer’s Brain Tissue
por: Ni, Ruiqing, et al.
Publicado: (2021)

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
por: Rubinski, Anna, et al.
Publicado: (2022)

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study
por: Mattsson, Niklas, et al.
Publicado: (2018)

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
por: Smith, Ruben, et al.
Publicado: (2020)

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
por: Lemoine, L., et al.
Publicado: (2020)

Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948
por: Smith, Ruben, et al.
Publicado: (2019)

Impulsive-compulsive behaviour in early Parkinson’s disease is determined by apathy and dopamine receptor D3 polymorphism
por: Theis, Hendrik, et al.
Publicado: (2023)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Comparison of New Tau PET-Tracer Candidates With [(18)F]T808 and [(18)F]T807
por: Declercq, Lieven, et al.
Publicado: (2016)

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kg6pkg5av5073pp3t8njqopnkg